2025 RSV Infant Protection Program concluding on 30 September 2025

The 2025 RSV Infant Protection Program (monoclonal antibody, mAb) will conclude on 30 September 2025, and no additional Beyfortus (Nirsevimab) doses will be given after 1 October 2025.

Note:  The National Maternal RSV Immunisation Program for pregnant women is ongoing (Abrysvo vaccine).

The mAb program for unprotected infants is offered on a seasonal schedule and is being considered to resume on 1 April 2026, with more details to be confirmed in early 2026.

Make sure to minimise your stock levels over the next 4 weeks.  Any remaining doses of Beyfortus must be appropriately stored until expiry.

Expiry date of all stock is 31 August 2026 and must be safely stored until this date.